Welcome to part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs),
Why the FDA animal testing phase-out for monoclonal antibodies?
In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal
The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches
New modality drugs, or advanced oligonucleotide therapeutics, refer to innovative approaches that go beyond traditional small molecule approaches to
Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?
In the realm of pharmaceutical research, Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and
User Group Meeting 2024 – Recap
6 Challenges in ADME Drug Development
When developing drugs, we rely heavily on in vitro, in vivo animal and in silico models to predict how the human body will interact with drugs before
How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
Imagine a world where developing new medicines is faster, cheaper, and less reliant on the use of animals for testing. Novel multi-organ in vitro
Organ-on-a-chip adoption: The roadmap to broader use
Paving the way for Organ-on-a-chip adoption Drug discovery is becoming more complex as we move from a small molecule world to large molecules and
Global Fatty Liver Day 2024: How Organ-on-a-Chip Addresses R&D Challenges
To commemorate Global Fatty Liver Day on June 13, this article explores how organ-on-a-chip models are transforming liver disease research. Over